

PATENT
1110-0307P



IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: NAGATA et al. Conf.:
Appl. No.: Divisional of 09/297,328 Group: Unassigned
Filed: February 28, 2002 Examiner: UNASSIGNED
For: PROPHYLACTIC/THERAPEUTIC AGENT

#2 1/2

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Assistant Commissioner for Patents
Washington, DC 20231

February 28, 2002

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).
09/297,328

U.S. Filing Date(s)
April 29, 1999

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Gerald M. Murphy (by No. 40,069)
Gerald M. Murphy, Jr., #28,977

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/MAA/csp
1110-0307P

Enclosures: ☒ PTO-1449
☐ References
☐ Foreign Search Report
☐ Other:

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		ATTY DOCKET NO. 1110-0307P		APPLICATION NO. Divisional 09/297,328	
APPLICANT NAGATA et al.		FILING DATE February 28, 2002		GROUP Unassigned	

Jc872 U.S. P80
 10/084139
 02/28/02

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
	8208515	1996-08-13	JAPAN				
	9510540	1995-04-20	W.I.P.O.				
	9110722	1997-04-28	JAPAN				
	9124509	1997-05-13	JAPAN				
	9733617	1997-09-18	W.I.P.O.				
	9712632	1997-04-10	W.I.P.O.				
	9640041	1996-12-19	W.I.P.O.				
	9518819	1995-07-13	W.I.P.O.				

OTHER DOCUMENTS	
(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	GALLE et al., J. Exp. Med., Vol. 182, No. 5 (1995) pp. 1223-1230.
	M. Tanaka et al., Nature Medicine, Vol. 2, No. 3, March 1996, pp. 317-322.
	Derwent Publications Ltd., XP-002124972, November 7, 1995.
	M. Enari et al., Nature, Vol. 375, No. 6526, May 1995, pp. 78-81.
	T. KNODO et al., Nature Medicine, Vol. 3, No. 4, April 1997, pp. 409-413
EXAMINER _____ DATE CONSIDERED _____	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	